Staessen, J.A., Richart, T. and Birkenhager, W.H. (2007) Less Atherosclerosis and Lower Blood Pressure for a Meaningful Life Perspective with More Brain. Hypertension, 49, 389-400.
http://dx.doi.org/10.1161/01.HYP.0000258151.00728.d8

has been cited by the following article:

• TITLE: Sulodexide and Alzheimer’s Disease: A Preliminary Prospective Study

  AUTHORS: Joaquín Lasierra-Cirujeda, María José Aza Pascual-Salcedo, María Mercedes Aza Pascual-Salcedo

  KEYWORDS: Sulodexide, Alzheimer’s Disease, Glutathione, t-PA, PAI-1, Plasminogen, Plasmin

  JOURNAL NAME: World Journal of Cardiovascular Diseases, Vol.6 No.2, February 24, 2016

  ABSTRACT: The purpose of this prospective study is to determine the relative incidence of Alzheimer’s disease in patients treated for at least three years, with sulodexide (n = 46, 76.48 ± 7.02 years old) or acenocoumarol (n = 47, 78.21 ± 6.66 years old) in order to prevent primary and secondary venous thromboembolism and atherothrombotic disease. In the sulodexide group, there was an apparent prevention of cognitive and behavioural impairment (relative incidence: 2.02) compared with acenocoumarol group (relative incidence: 4.86). The favourable results in sulodexide group may be related to their pharmacodynamic actions of inhibition of PAI-1, which may interfere with the pathogenesis of Alzheimer’s disease, and to the role of glutathione and PAI-1 in the β-amyloid system in the brain.